Sol-Gel Technologies Ltd. Forecasted to Earn Q2 2024 Earnings of ($0.19) Per Share (NASDAQ:SLGL)

Sol-Gel Technologies Ltd. (NASDAQ:SLGL) – HC Wainwright reduced their Q2 2024 earnings estimates for Sol-Gel Technologies in a research report issued to clients and investors on Wednesday, May 22nd. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.19) per share for the quarter, down from their previous forecast of ($0.14). HC Wainwright has a “Buy” rating and a $6.00 price target on the stock. The consensus estimate for Sol-Gel Technologies’ current full-year earnings is ($0.83) per share. HC Wainwright also issued estimates for Sol-Gel Technologies’ Q3 2024 earnings at ($0.21) EPS, Q4 2024 earnings at ($0.20) EPS, FY2024 earnings at ($0.83) EPS, Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.09) EPS and FY2025 earnings at ($0.55) EPS.

Sol-Gel Technologies Stock Performance

Shares of NASDAQ:SLGL opened at $0.80 on Friday. The firm’s 50 day moving average is $0.88 and its two-hundred day moving average is $1.10. Sol-Gel Technologies has a 52 week low of $0.63 and a 52 week high of $4.05. The firm has a market capitalization of $22.29 million, a P/E ratio of -0.96 and a beta of 1.38.

Sol-Gel Technologies (NASDAQ:SLGL) last released its quarterly earnings data on Wednesday, March 13th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.01). Sol-Gel Technologies had a negative return on equity of 56.20% and a negative net margin of 1,329.13%. The business had revenue of $0.45 million for the quarter, compared to analyst estimates of $0.27 million.

About Sol-Gel Technologies

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc, develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.